International Journal of Radiation Oncology*Biology*PhysicsCancer BiologyPeer-reviewed journal article
Interferon signaling underlies radiotherapy responses in malignant peripheral nerve sheath tumors (MPNSTs)
Iowis ZhuiD, Julian Chien, Kanish MirchiaiD, Sixuan PaniD, Kaeli Miller, Joanna Pak, Rosanna Wustrack, Varun MongaiD, Steven E. Braunstein, Line G JacquesiD, Melike PekmezciiD, S. John Liu, Harish N. VasudevaniD
Abstract
Malignant peripheral nerve sheath tumors (MPNSTs) have poor outcomes despite multimodal treatment with surgery, radiation, and systemic therapy. Here, we combine bulk and single cell transcriptomics, genome wide CRISPRi screens, and multiplatform molecular analysis across MPNST cells, mouse allograft models, and human patient samples to understand the mediators of radiation response. Our data reveal MPNSTs induce a type I interferon signature that functionally underlies radiation response. Moreover, irradiation of immunocompetent mouse MPNST allografts leads to interferon mediated T-cell recruitment and activation. Analysis of human MPNST resection specimens demonstrates increased microenvironmental and CD8+ T-cell infiltration are associated with improved local control following radiotherapy while chromosome 9p loss, which harbors an interferon gene cluster, is associated with poor radiotherapy response and decreased CD8+ T-cell infiltration. Taken together, these results provide preclinical rationale for combining immunomodulatory agents targeting interferon signaling to improve radiation responses in MPNSTs, which may be broadly applicable to other soft tissue sarcomas.
- organism: mouse
- organism: human
- assay: bulk RNA-seq
- assay: scRNA-seq
- research focus: host-pathogen & immune response
- research focus: cell type annotation
- approach: genetic perturbation / CRISPR
- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 29th percentile
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Targeting STING-ATM axis overcomes radiotherapy-induced immune suppression and restores anti-tumor immunity in nasopharyngeal carcinoma
Tzu-Tung Liu, Kai-Ping Chang, … Shu‐Chen Liu·bioRxiv·Nov 12, 2025
- Effects of clinically relevant radionuclides on the activation of a type I interferon response by radiopharmaceuticals in syngeneic murine tumor models
Caroline P. Kerr, Julia Sheehan‐Klenk, … Zachary Scott Morris·Cancer Immunology ResearchPeer-reviewed·May 29, 2025
- Intratumoral plasma cells are required for activation of CD8+ T cells and success of immune checkpoint blockade therapy in de novo MPNSTs
Joshua J. Lingo, Ryan J. Reis, … Dawn E. Quelle·bioRxiv·Feb 20, 2026
- Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy
M. Yazdimamaghani, O. Kolupaev, … J. Serody·bioRxiv·Mar 9, 2024
- Activating neutrophils by co-administration of immunogenic recombinant modified vaccinia virus Ankara and granulocyte colony-stimulating factor for the treatment of malignant peripheral nerve sheath tumor
- Redundant roles of YES and SRC tyrosine kinases in driving malignant peripheral nerve sheath tumors
Elamine Zereg, Laure Voisin, … Sylvain Meloche·bioRxiv·Feb 20, 2026